Eli Lilly's retatrutide — commonly referred to as reta in patient communities — has cleared a landmark Phase 3 clinical trial, bringing the company meaningfully closer to filing for FDA approval. According to reporting from CNBC, this milestone represents one of the most significant developments in obesity medicine in years, and it comes backed by data that is rewriting what patients and clinicians believe is possible in non-surgical weight management.
The trial in question — TRIUMPH-4 — ran for 68 weeks and evaluated retatrutide at doses of 9mg and 12mg administered as a once-weekly subcutaneous injection. The headline result: a mean weight loss of 28.7% at the 12mg dose. That figure is not a rounding error. It is the highest mean weight loss ever recorded in a Phase 3 obesity trial, and it places retatrutide in a category of its own among currently available and investigational therapies.
To appreciate what "clearing a crucial obesity trial" means in practical terms, it helps to understand the regulatory pathway. Phase 3 trials are the final large-scale efficacy and safety studies required before a company can file a New Drug Application (NDA) with the FDA. With TRIUMPH-4 data now in hand, Eli Lilly is positioned to move toward that filing — though as of April 2026, no NDA has been submitted and no FDA approval timeline has been publicly confirmed.
Retatrutide is a triple hormone receptor agonist, meaning it simultaneously activates three distinct metabolic pathways: the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This sets it apart from every other approved obesity medication on the market today. Sometimes called a "triple G" by those following its development closely, this triple agonist mechanism represents a fundamentally different pharmacological strategy than existing options.
To understand why this matters clinically, consider what each receptor does:
This combination is why retatrutide is administered as an injection rather than an oral tablet — the peptide structure requires subcutaneous delivery to maintain stability and bioavailability. The once-weekly injection format mirrors that of semaglutide (Wegovy) and tirzepatide (Zepbound), both of which patients and clinicians are already familiar with.
The comparison table below places retatrutide's Phase 2 and Phase 3 results in context alongside the pivotal trials for currently approved GLP-1-based therapies:
| Drug | Mechanism | Trial | Duration | Mean Weight Loss (Highest Dose) |
|---|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 agonist | STEP-1 | 68 weeks | ~14.9% |
| Tirzepatide (Zepbound) | GLP-1 / GIP dual agonist | SURMOUNT-1 | 72 weeks | ~20.9% |
| Retatrutide (investigational) | GLP-1 / GIP / Glucagon triple agonist | TRIUMPH-4 (Phase 3) | 68 weeks | 28.7% |
The Phase 2 data published in the New England Journal of Medicine in 2023 (Jastreboff et al., NCT04881760) foreshadowed this result. At 48 weeks, participants receiving the 8mg dose achieved a mean weight loss of approximately 22.8%, with up to 70% of that group losing 20% or more of their body weight. At the 12mg dose, mean weight loss reached approximately 24.2%, with 48% of participants achieving 25% or greater weight reduction. These Phase 2 figures were already unprecedented — and the Phase 3 results have surpassed them.
Clearing TRIUMPH-4 means Eli Lilly now has the pivotal efficacy and safety data needed to pursue a regulatory submission. The anticipated next steps include compiling the full clinical dossier — encompassing Phase 2 and Phase 3 trial data, safety follow-up, manufacturing information, and labeling proposals — and submitting an NDA to the FDA.
On the safety side, the TRIUMPH-4 data revealed a profile broadly consistent with the GLP-1 drug class, though with some dose-dependent signals worth noting. Discontinuation rates were 12.2% at the 9mg dose and 18.2% at 12mg, compared to 4.0% for placebo. Notably, some discontinuations occurred because participants felt they were losing weight too rapidly — an unusual reason by historical standards, but a reflection of how potent this drug is. Dysesthesia (abnormal skin sensations) was reported in 8.8% of the 9mg group and 20.9% of the 12mg group, compared to 0.7% on placebo. This signal was also observed in Phase 2 data, where hyperesthesia and dysesthesia were reported in 12.9% of the 12mg group versus 1.4% on placebo, making it an anticipated and monitored finding rather than a surprise.
Gastrointestinal side effects — nausea, diarrhea, and vomiting — remain the most common adverse events, consistent with the broader GLP-1 drug class. These were dose-dependent and most pronounced during the titration phase in Phase 2 data.
As of April 2026, Eli Lilly has not yet filed an NDA for retatrutide, and no FDA approval timeline has been publicly confirmed. The peer-reviewed Phase 3 publication from TRIUMPH-4 is also still pending. Once an NDA is submitted, the FDA's standard review window is typically 12 months, with the possibility of Priority Review designation reducing that to 6 months. Given the unmet need in obesity medicine and the strength of the efficacy data, priority designation is plausible — but not yet granted or confirmed.
For patients managing obesity today, the honest answer is that retatrutide is not yet available outside of clinical trials. What is known is that the trajectory is positive, the data are compelling, and the regulatory machinery is now in motion.
For those following the retatrutide story closely — whether because existing therapies have not delivered sufficient results, or because the Phase 3 data has sparked genuine hope — staying informed and positioned is the most actionable step available right now. The food noise that drives so much of the struggle with obesity is real, and for many patients, the data behind retatrutide represents the first time a pharmacological option has appeared genuinely capable of addressing it at its root.
glp3md.com maintains a retatrutide waitlist designed to keep interested patients informed as the regulatory landscape evolves. Joining the waitlist at https://www.glp3md.com does not constitute enrollment in a clinical trial, and it does not represent a promise or guarantee of access to medication, treatment, or a prescription of any kind. Retatrutide is not FDA-approved, and the waitlist exists solely to provide timely, clinically grounded information as new developments emerge. If and when the regulatory pathway advances, those on the waitlist will be among the first to know.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.